摘要
目的：探讨米力农治疗顽固性心力衰竭的有效性和安全性。方法：收集2012年1月-2014年6月本院ICU内60例经常规抗心衰治疗无效的顽固性心力衰竭患者资料,随机数字表法分为硝普钠组（n=30）和米力农组（n=30）。硝普钠组予硝普钠0.5-3μg/（kg·min）静脉维持,米力农组予米力农0.5μg/（kg·min）静脉维持,连续使用3 d,观察有效性和安全性,并行心脏彩超检查。结果：硝普钠组有28例纳入分析,米力农组有25例纳入分析。硝普钠组和米力农组7 d有效率分别为64.3%和96.0%,比较差异有统计学意义（P〈0.05）。硝普钠组和米力农组治疗后BNP比较差异有显著统计学意义（P〈0.05）,米力农组治疗后左室射血分数、舒张早期/舒张晚期心室充盈速度、每搏量、心指数均显著优于硝普钠组（P〈0.05）。两组治疗后左室舒张末期内径比较差异无统计学意义。硝普钠组有2例（6.7%）患者发生顽固性低血压,米力农组有5例（16.7%）患者发生恶性心律失常,两组比较差异无统计学意义。结论：米力农提高顽固性心力衰竭抢救成功率、改善心功能。
Objective： To investigate the effectiveness and safety of milrinone in treatment to refractory heart failure. Method： During January 2012 to June 2014, 60 patients with refractory heart failure were divided into sodium nitroprusside group（n=30） and milrinone group（n=30）. The dosage of sodium nitroprusside and milrinone were 0.5-3 μg/（kg·min）min and 0.5 μg/（kg·min）, which the time of duration was 3 days. Result： 28 patients in sodium nitroprusside group and 25 patients in milrinone group were included in the analysis. 7-day effectiveness of the milrinone group was significantly higher than that of the sodium nitroprusside group（P〈0.05）. BNP of the milrinone group after treatment was significantly lower than that of the sodium nitroprusside group（P〈0.05）. There were significant differences in LVEF, E/A, SV, CI between the two groups（P〈0.05）. There was no significant difference in incidence of adverse events between the two groups. Conclusion： Milrinone can improve the success rate of rescue in patients with Refractory heart failure.
出处
《中国医学创新》
CAS
2015年第1期71-73,共3页
Medical Innovation of China
